Synektik (SNTP) Q4 2025 earnings summary

Executive summary

• Achieved PLN 681.3 million in revenue and PLN 177.1 million EBITDA from continuing operations for Q1–Q4 FY2024, representing 9% and 24% year-over-year growth, respectively.

• Net profit from continuing operations rose 27% year-over-year to PLN 125.2 million, with total comprehensive income up 24% to PLN 102.1 million.

• Record recurring revenue and strong order backlog, driven by robust demand in medical equipment and IT solutions, and growth in radiopharmaceuticals.

• Strategic spin-off of the New Molecule Research Center and cardiac-tracer/R&D business into Syn2bio S.A., with positive court assessment and prospectus submitted to the regulator.

• Strong performance in the medical equipment and IT segment, with recurring revenues up 60% year-over-year and a 29% increase in segment EBITDA.

Financial highlights

• Q4 FY2024 consolidated revenue reached PLN 199.2 million, up 41% year-over-year; EBITDA from continuing operations was PLN 54.6 million (+61% YoY); net profit from continuing operations was PLN 39.4 million (+72% YoY).

• Equipment and IT solutions segment revenue grew 46% YoY in Q4, with EBITDA up 70% to PLN 60.1 million.

• Radiopharmaceuticals segment Q4 revenue was PLN 12.2 million (down 4% YoY), with EBITDA at PLN 3.2 million.

• Net loss from business designated for spin-off increased to PLN 23.0 million for Q1–Q4 FY2024, mainly due to higher clinical trial costs.

• Cash surplus over financial liabilities stood at nearly PLN 44 million as of September 30, 2025.

Outlook and guidance

• Entering FY2025 with a record order backlog and active offers totaling nearly PLN 275 million, a 55% year-over-year increase.

• Continued strong demand expected for medical equipment, supported by ongoing hospital tenders and KPO-funded healthcare investments.

• Expansion in da Vinci system installations and procedures anticipated, despite changes in reimbursement levels.

• Ongoing development in surgical robotics, new product launches, and expansion of radiopharmaceuticals portfolio are key growth drivers.

• No financial forecasts for FY2025 were published.